Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05629494 · ClinicalTrials.gov registry record · Phase 4

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

A Phase 4 study of Prostate Cancer and PSA, sponsored by Albany Medical College.

Recruiting
Registry status
Phase 4
Development phase
198
Enrollment target
3
Study locations

NCT05629494: Recruiting Phase 4 study of Prostate Cancer and PSA, sponsored by Albany Medical College.

NCT05629494 is a Phase 4 study of Prostate Cancer and PSA that is actively recruiting participants, run by Albany Medical College. The registered enrollment target is 198 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05629494, a Phase 4 study of Prostate Cancer and PSA, is actively recruiting participants, sponsored by Albany Medical College.

RECRUITING
Registry status
Phase 4
Development phase
198 participants
Enrollment target
3
Study locations

Study Summary

Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation in the level. Investigators plan to treat men with elevated PSA level with over the counter anti-inflammatory medications (ibuprofen, naproxen) to see if the PSA level will decrease to an acceptable level.

Primary Outcome

Difference in PSA levels, within and between groups

Interventions

  • DRUG Ibuprofen 400 mg, TID
  • DIAGNOSTIC_TEST PSA test

Study Locations (3)

Illinois

  • University of Chicago Medical Center - Chicago

New York

  • Albany Medical Center - Albany

Pennsylvania

  • Penn State-Hershey Medical Center - Hershey

Trial Details

FieldValue
Enrollment Target 198 participants
Start Date 2022-09-27
Est. Completion 2026-12-01
Phase Phase 4
Albany Medical College

52 total trials

What NCT05629494 shows while recruiting

NCT05629494 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower).

The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ibuprofen 400 mg, TID is the first listed.

NCT05629494 reports a single indexed study location in Illinois, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05629494 about?

NCT05629494 is a clinical study titled "Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test". Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at th...

What is the current status of trial NCT05629494?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 198 participants. The study started on 2022-09-27. Estimated completion is 2026-12-01.

What conditions does trial NCT05629494 study?

This clinical trial studies the following conditions: Prostate Cancer, PSA, Prostate Inflammation.

What interventions are being tested in trial NCT05629494?

The interventions under investigation include: Ibuprofen 400 mg, TID (DRUG), PSA test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05629494?

This trial is sponsored by Albany Medical College, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05629494 being conducted?

This trial has 3 study locations across Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05629494's enrollment target sits among peer trials

198 233rd of 735 higher than 503 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05203328 · 198 participants · NA

    Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy

  • NCT05426967 · 198 participants · NA

    rTMS for Military TBI-related Depression

  • NCT05561114 · 198 participants · Phase 3

    Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

  • NCT05585190 · 198 participants · NA

    Stand Up for Your Health with a Sit-stand Desk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05629494, the US trial registry maintained by the National Library of Medicine. NCT05629494 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.